ArticleCancer discovery2017
Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness.
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The prognostic value of PI3K mutational status in breast cancer: A meta-analysis.Journal of cellular biochemistry · 2018Pooled it
- Exploring the promise of regulator of G Protein Signaling 20: insights into potential mechanisms and prospects across solid cancers and hematological malignancies.Cancer cell international · 2024Review
- Venous Malformations.Seminars in interventional radiology · 2022Review
- Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future.Frontiers in oncology · 2022Review
- The duality of human oncoproteins: drivers of cancer and congenital disorders.Nature reviews. Cancer · 2020Review
- A PI3K- and GTPase-independent Rac1-mTOR mechanism mediates MET-driven anchorage-independent cell growth but not migration.Science signaling · 2020Article
- Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.Breast cancer research : BCR · 2020Review
- Identification of the possible therapeutic targets in the insulin-like growth factor 1 receptor pathway in a cohort of Egyptian hepatocellular carcinoma complicating chronic hepatitis C type 4.Drug target insights · 2020Article
- PI3K Inhibitors in Breast Cancer Therapy.Current oncology reports · 2019Review
- Overview of the relevance of PI3K pathway in HR-positive breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Review
- Emerging serine-threonine kinase inhibitors for treating ovarian cancer.Expert opinion on emerging drugs · 2019Article
- Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells.Cancers · 2019Article
- PDK1 MediatesClinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells.International journal of molecular sciences · 2019Review
- Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.Drug safety · 2019Review
- The Role of PI3K in Met Driven Cancer: A Recap.Frontiers in molecular biosciences · 2018Review
- Development of Molecularly Driven Targeted Combination Strategies.The oncologist · 2017Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<b/> Excitement and drug-development efforts aimed at targetable genetic aberrations in the PI3K/AKT/mTOR pathway have declined due to the limited clinical performance of these inhibitors as monotherapies. New, more isoform-selective treatments, such as taselisib, promise to both expand the therapeutic window and increase efficacy.
Indexed as
Identifiers
28684409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.